Search

Displaying results 2611 - 2620 of 10000 in total
  1. Drug

    Human botulinum neurotoxin A/B immune globulin

    go.drugbank.com/drugs/DB14115
    Approved

    Infant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. … [L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism.

    Synonyms: Botulism immune globulin IV human, Botulism immune globulin intravenous (human) (BIG-IV)
  2. Drug

    Retapamulin

    go.drugbank.com/drugs/DB01256
    Approved

    Retapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo. It was approved by the FDA in April 2007.

  3. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [L51973] When administered alongside glucocorticoid replacement in patients with CAH it allows for the use of lower, physiological doses for glucocorticoid replacement, thereby reducing the risks associated

  4. Drug

    Trimethadione

    go.drugbank.com/drugs/DB00347
    ApprovedWithdrawn

    An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)

  5. Drug

    Azacitidine

    go.drugbank.com/drugs/DB00928
    ApprovedInvestigational

    [A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335] … Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.

  6. Drug

    Talazoparib

    go.drugbank.com/drugs/DB11760
    ApprovedInvestigational

    [L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and by the EMA in June 2019.[L47296] It was approved by Health Canada in September 2020. … [L47301] Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306]

  7. Drug

    Metyrosine

    go.drugbank.com/drugs/DB00765
    ApprovedInvestigational

    It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) … An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines.

  8. Drug

    Carbocromen

    go.drugbank.com/drugs/DB13279
    ApprovedWithdrawn

    Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].

    Categories: Vasodilators Used in Cardiac Diseases
  9. Drug

    Fosamprenavir

    go.drugbank.com/drugs/DB01319
    ApprovedInvestigational

    Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.

  10. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. … Regorafenib is an orally-administered inhibitor of multiple kinases.